Produce additional quantities of the final product for the needs of Phase II clinical study, conduct the Phase II clinical study to evaluate the safety and efficacy of a new formulation of OSTEOGROW (OSTEOproSPINE) for spinal fusion and relief of lumbar back pain in patients with degenerative disc disease compared with autologous bones and obtain the first clinical evidence of the effectiveness and safety of two doses of OSTEOproSPINE for PLIF compared with autologous bone grafting and develop the basis for a range of products that can form bone on the ectopic place.